BioXcel Therapeutics, Inc. (BTAI) Social Stream



BioXcel Therapeutics, Inc. (BTAI): $12.03

0.29 (+2.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BioXcel Therapeutics Inc (BTAI) Price Targets From Analysts

Use the tables below to see what analysts covering BioXcel Therapeutics Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-10 6 $140 $75 $101.375 $21.69 367.38%
2021-12-16 7 $140 $75 $101.375 $21.69 367.38%
2022-01-13 7 $140 $73 $99.75 $21.69 359.89%
2022-02-01 7 $140 $73 $99.428 $21.69 358.4%
2022-03-10 6 $140 $73 $99.428 $21.69 358.4%
2022-03-18 6 $130 $73 $98 $21.69 351.82%

The Trend in the Analyst Price Target


BTAI's average price target has moved up $11.71 over the prior 22 months.

BTAI reports an average of 287.52% for its upside potential over the past 50 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-25 9 175 63 102.670 34.50 197.59%
2021-08-07 9 145 63 100.460 26.20 283.44%
2021-09-11 9 140 48 92.550 29.44 214.37%
2021-11-30 7 140 75 101.375 22.93 342.11%
2022-02-01 7 140 73 99.428 16.89 488.68%

BTAI Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 6 0 0 0 0 6

The Trend in the Broker Recommendations


Over the past 151 days, BTAI's average broker recommendation rating improved by 0.6.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • BioXcel Therapeutics Inc's upside potential (average analyst target price relative to current price) is higher than 564.12% of all US stocks.
  • In the context of stocks in the small market cap category, BioXcel Therapeutics Inc's average analyst price target is greater than 588.94% of them.
  • In the context of stocks in the small market cap category, BioXcel Therapeutics Inc's number of analysts covering the stock is higher than 493.44% of them.
  • BTAI has a lower variance in analysts' estimates than -358.17% of stocks in the small market cap category.

In the Pharmaceutical Products industry, BPTH, BOLT, and BLU are the three stocks most similar to BioXcel Therapeutics Inc regarding the price target and analyst recommendation information presented here.

Is BTAI a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.9247 seconds.